Indications for breast cancer should be left to EOC our Chinese partner.
Management is concentrating on the most likely to be approved and profitable indications.
IMM has world wide patents for eftilagimod/PD1 combination therapy. GSK, BMS and others will want in on the action.
lag525 is another check point inhibitor. No reason it couldn’t be used with eftilagimod/pd1 therapy
Ann: Appendix 4E & 2022 Full Year Statutory Accounts, page-7
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |